Albert David Ltd
Incorporated in 1938, Albert David
Ltd is in the business of manufacturing pharmaceutical products[1]
- Market Cap ₹ 467 Cr.
- Current Price ₹ 817
- High / Low ₹ 1,754 / 763
- Stock P/E 27.1
- Book Value ₹ 688
- Dividend Yield 1.41 %
- ROCE 6.48 %
- ROE 4.44 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Stock is trading at 1.19 times its book value
Cons
- The company has delivered a poor sales growth of 1.57% over past five years.
- Company has a low return on equity of 12.5% over last 3 years.
- Earnings include an other income of Rs.29.6 Cr.
- Dividend payout has been low at 13.2% of profits over last 3 years
- Working capital days have increased from 94.2 days to 274 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
287 | 317 | 318 | 293 | 285 | 316 | 320 | 246 | 313 | 341 | 362 | 346 | |
254 | 281 | 286 | 266 | 267 | 286 | 289 | 227 | 272 | 297 | 315 | 343 | |
Operating Profit | 33 | 37 | 31 | 27 | 18 | 30 | 30 | 19 | 41 | 44 | 47 | 3 |
OPM % | 11% | 12% | 10% | 9% | 6% | 10% | 10% | 8% | 13% | 13% | 13% | 1% |
1 | 2 | 43 | 8 | 9 | 15 | 7 | 17 | 16 | 15 | 58 | 30 | |
Interest | 4 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 |
Depreciation | 11 | 15 | 9 | 8 | 8 | 7 | 8 | 8 | 9 | 9 | 7 | 7 |
Profit before tax | 18 | 20 | 63 | 26 | 18 | 38 | 29 | 27 | 47 | 51 | 97 | 25 |
Tax % | 32% | 32% | 24% | 39% | 45% | 29% | 34% | 19% | 25% | 29% | 22% | 32% |
13 | 14 | 48 | 16 | 10 | 27 | 19 | 22 | 35 | 36 | 75 | 17 | |
EPS in Rs | 22.02 | 24.00 | 84.10 | 27.96 | 17.24 | 46.68 | 33.59 | 38.79 | 61.78 | 63.38 | 132.15 | 30.14 |
Dividend Payout % | 23% | 23% | 7% | 20% | 32% | 13% | 21% | 15% | 15% | 14% | 9% | 17% |
Compounded Sales Growth | |
---|---|
10 Years: | 1% |
5 Years: | 2% |
3 Years: | 3% |
TTM: | -4% |
Compounded Profit Growth | |
---|---|
10 Years: | 2% |
5 Years: | -2% |
3 Years: | -20% |
TTM: | -77% |
Stock Price CAGR | |
---|---|
10 Years: | 9% |
5 Years: | 10% |
3 Years: | 15% |
1 Year: | -30% |
Return on Equity | |
---|---|
10 Years: | 11% |
5 Years: | 12% |
3 Years: | 13% |
Last Year: | 4% |
Balance Sheet
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
Reserves | 85 | 87 | 131 | 177 | 180 | 205 | 217 | 239 | 274 | 306 | 377 | 387 |
42 | 30 | 20 | 30 | 28 | 0 | 2 | 2 | 6 | 5 | 3 | 12 | |
66 | 71 | 67 | 71 | 76 | 84 | 95 | 95 | 116 | 106 | 112 | 107 | |
Total Liabilities | 198 | 193 | 224 | 285 | 290 | 295 | 320 | 341 | 401 | 423 | 498 | 511 |
67 | 49 | 44 | 87 | 83 | 77 | 91 | 84 | 88 | 80 | 83 | 99 | |
CWIP | 3 | 5 | 5 | 9 | 5 | 5 | 2 | 1 | 1 | 3 | 7 | 2 |
Investments | 16 | 16 | 48 | 59 | 68 | 113 | 122 | 138 | 183 | 193 | 273 | 260 |
111 | 122 | 127 | 130 | 134 | 99 | 106 | 119 | 130 | 148 | 135 | 151 | |
Total Assets | 198 | 193 | 224 | 285 | 290 | 295 | 320 | 341 | 401 | 423 | 498 | 511 |
Cash Flows
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
21 | 28 | 68 | 20 | 30 | 32 | 30 | 37 | 40 | 11 | 46 | -28 | |
-24 | -9 | -38 | -36 | -11 | -19 | -20 | -37 | -40 | -5 | -33 | 23 | |
-2 | -18 | -18 | 7 | -5 | -17 | -10 | -2 | -2 | -6 | -8 | 0 | |
Net Cash Flow | -5 | 1 | 12 | -10 | 15 | -4 | 0 | -2 | -1 | -1 | 4 | -5 |
Ratios
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 54 | 47 | 41 | 41 | 35 | 25 | 34 | 29 | 29 | 32 | 30 | 29 |
Inventory Days | 191 | 176 | 187 | 217 | 173 | 151 | 148 | 151 | 124 | 149 | 126 | 201 |
Days Payable | 135 | 103 | 102 | 117 | 127 | 102 | 132 | 104 | 96 | 95 | 98 | 118 |
Cash Conversion Cycle | 111 | 120 | 126 | 141 | 81 | 74 | 50 | 76 | 57 | 87 | 58 | 112 |
Working Capital Days | 57 | 52 | 48 | 61 | 45 | 22 | 18 | -8 | -29 | 19 | -10 | 274 |
ROCE % | 18% | 18% | 17% | 15% | 7% | 18% | 14% | 12% | 17% | 17% | 28% | 6% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
14 May - Newspaper publication of Extract of Audited Financial Results for the quarter and year ended 31st March 2025
-
Integrated Filing (Financial)
14 May - Audited Q4 and FY2025 financial results filed; no deviations or defaults reported.
- Corporate Action - Fixes Record Date For The Purpose Of Dividend And 86Th AGM Is 25Th July 2025 13 May
-
Re-Appointment Of Cost Auditors
13 May - Albert David approved FY25 audited results, declared Rs.5 final dividend, reappointed auditors, AGM on Aug 2, 2025.
-
Appointment Of Secretarial Auditors
13 May - Albert David approved FY25 audited results with profit, recommended Rs.5 dividend, and appointed auditors for FY26.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1]
ADL is a part of the Kolkata-based Kothari Group. It is a prominent drug house, which is in the field of manufacturing Pharmaceutical Formulations, Infusion Solutions, Herbal Dosage Forms, Bulk Drugs, etc. Company is in strategic liaison with academic institutes like the Indian Institute of Chemical Biology (CSIR) & Department of Biotechnology, Calcutta University for outsourcing research.